MoonLake rises as spine‑inflammation drug shows benefit, secures new funding

MoonLake Immunotherapeutics

23/02/2026 11:23

** Shares of Swiss biotech MoonLake Immunotherapeutics MLTX.O rise 8.1% to $20.29 premarket

** Co says its experimental drug sonelokimab improved symptoms in a mid-stage trial for axial spondyloarthritis, a spine-inflammation disease

** MLTX says 81% of patients saw meaningful improvement at 12 weeks, with no new safety issues

** It amended its loan pact with Hercules Capital, giving the company access to up to $500 mln as development milestones are met - MLTX

** Seperately, Chairman of the board Simon Sturge to step down; Jorge Santos da Silva named interim chair, per co

** Shares down 77% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))